Maze Therapeutics (MAZE) Accumulated Expenses (2024 - 2026)

Maze Therapeutics has reported Accumulated Expenses for 3 years, with the latest figure at $5.4 million in Q1 2026.

• Quarterly Accumulated Expenses fell 53.07% year-over-year to $5.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.4 million (down 53.07% YoY) and the FY2025 annual result came in at $10.9 million, down 23.04% from the prior year.
• Accumulated Expenses retreated to $5.4 million in Q1 2026 per MAZE's latest filing, from $10.9 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $14.4 million in Q3 2025 and troughed at $5.4 million in Q1 2026.
• A 3-year average of $11.3 million and a median of $11.5 million in 2025 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2025 and 2026: Accumulated Expenses dropped 23.04% in 2025, then plunged 53.07% in 2026.
• Over 3 years, Accumulated Expenses stood at $14.1 million in 2024, then fell by 23.04% to $10.9 million in 2025, then tumbled by 50.11% to $5.4 million in 2026.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $5.4 million, $10.9 million, and $14.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.